首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1410051

2023年至2028年大腸篩檢市場預測

Colorectal Cancer Screening Market - Forecasts from 2023 to 2028

出版日期: 2023年12月15日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2021年大腸篩檢市場規模為16.39億美元，預估預測期間內複合年成長率為5.55%。

隨著老齡化的成長，結腸和直腸內壁上形成的稱為息肉的非癌性生長物是大腸最常發生的地方。由於生活方式的改變、糖尿病和肥胖，大腸盛行率不斷上升，這是大腸篩檢市場的主要成長動力。此外，人口中吸菸文化的增加以及老年人口的增加預計也會增加大腸的風險並推動大腸腸癌篩檢市場。人們對大腸負面影響的認知不斷提高，市場參與企業透過推出產品來提高可及性，預計將進一步擴大大腸篩檢市場。

大腸盛行率上升

大腸直腸癌患者數量的增加表明了篩檢的需求，這對大腸篩檢市場做出了積極貢獻。據世界衛生組織稱，2020 年，大腸確診病例超過 190 萬例，成為全球第三大常見癌症類型。據美國癌症協會稱，在美國，預計 2023 年將確診 153,020 例大腸(CRC) 新病例，導致 52,550 人死亡。

改變你的生活方式和飲食習慣

典型的西方飲食脂肪和熱量高，膳食纖維含量低，可能與大腸癌有關，而大腸癌更容易發生在不運動的人身上。根據 NCBI 的數據，美國成年人平均每天坐著的時間為 7.7 小時，韓國成年人為 8.3 小時。據世界衛生組織稱，世界上超過80%的年輕人沒有得到足夠的鍛煉，導致許多嚴重的健康問題，包括大腸。因此，久坐生活方式的採用有望培育大腸篩檢市場。

吸煙人口增加

大腸直腸癌（CRC）的一個重要危險因子是吸菸。 NCBI 研究發現，吸菸會顯著增加動物模型中結直腸癌形成的風險以及人類大腸直腸癌的發病率和死亡率。根據世界衛生組織統計，2020年，全球有36.7%的男性和7.8%的女性消費菸草，佔全球人口的22.3%。根據英國癌症研究中心的數據，在英國，2021 年有 690 萬名成年吸菸者，佔成年人（18 歲及以上）的 13.3%。如此龐大的吸菸人口預示著大腸病例數將很快增加，大腸篩檢市場也將擴大。

人口老化與慢性發炎疾病

大多數大腸直腸癌發生在 50 歲以上的人群中。根據梅奧診所的一份報告，50 歲以下人群的結腸癌發生率正在增加。根據美國癌症協會統計，147,950 例大腸病例中有 80,010 例為 65 歲及以上。因此，老年人口的增加預計將加強大腸篩檢市場。例如，根據世界衛生組織估計，60歲及以上人口預計將從2020年的10億增加到2030年的14億。

提高對大腸直腸癌的認知

旨在提高人們認知的多項宣傳活動加上技術創新正在積極推動大腸篩檢市場。例如，在美國，作為 CDC 生命篩檢計畫的一部分，正在對 45 歲及以上的人群進行定期大腸篩檢的價值的教育。作為全國大腸癌行動運動的一部分，我們正在對 45 歲及以上的人群進行有關定期大腸篩檢的價值的教育。此外，2023年4月，國際癌症研究機構發布了關於五大洲癌症篩檢的Can5舉措的第一份報告。

北美地區預計將大幅成長

預計北美地區在預測期內將佔據大腸篩檢市場的重要佔有率。造成這一比例的因素包括受過高等教育的人口、政府計劃以及導致大腸疾病的高盛行率，例如吸煙和久坐的生活方式。例如，根據CDC的資料，約有1,600名18歲以下的美國青少年每天第一次點煙，另有1,600萬人患有因吸菸引起的嚴重疾病。此外，Exact Science Corporation 和 Polymedco Inc. 等主要市場領導的出現預計將進一步推動大腸篩檢市場的發展。

市場主要發展

2023 年 3 月，CDC 與 CPCRN 和 NACCD 合作，宣布推出提高乳癌、子宮頸癌和大腸篩檢品質的工具。該計劃旨在支持社區努力提高癌症篩檢率並挽救更多生命。 2023 年 2 月，Sanora Quest Labs 推出了該公司首款大腸家庭篩檢套件InSure ONE。將檢查糞便樣本中的人體血紅蛋白，以檢查是否有下消化道出血，這是大腸的症狀。 2022 年 5 月，Guardant Health 宣布推出 Shield Test，可透過短時間抽血檢測大腸。此測試不需要時間、麻醉、特殊準備或用餐調整。識別血液中 CRC 訊號的早期跡象。

The noncancerous growth known as a polyp, which can appear on the inner wall of the colon or rectum as people age, is where colorectal cancer most frequently develops. The higher prevalence rate of colorectal cancer due to changing lifestyles, diabetes, and obesity are major growth drivers of the colorectal cancer screening market. Moreover, the increasing smoking culture among people coupled with the growing older population is also expected to increase the risk of colon cancer thereby propelling the colorectal cancer screening market. The increasing awareness about the adverse effects of colorectal cancer and product launches by the market players resulting in more accessibility are further contemplated to augment the colorectal cancer screening market.

Higher Prevalence of Colorectal Cancer

The rising colorectal cancer cases indicate the need for screening and thus contribute positively to the colorectal cancer screening market. With more than 1.9 million cases identified, colorectal cancer was the third most frequent cancer type in the world in 2020, according to the WHO. A projected 153,020 new cases of colorectal cancer (CRC) will be identified in the US in 2023, and 52,550 deaths are estimated as per the American Cancer Society.

Changing Lifestyle and Diet

A normal Western diet that is high in fat and calories and poor in fiber may be linked to colon and rectal cancer and Colon cancer is more prone to occur in those who are inactive. According to NCBI, the average amount of time spent sitting each day is 7.7 hours for adults in America and 8.3 hours for the Korean population. According to the WHO, over 80% of young people worldwide don't participate in enough physical activity leading to numerous serious health issues including colorectal cancer. Therefore, the adoption of a sedentary lifestyle is expected to aid the colorectal cancer screening market.

Growing Prevalence of Smoking among Population

A significant risk factor for colorectal cancer (CRC) is cigarette smoking. Smoking was found to dramatically increase the risk of CRC formation in animal models as well as CRC incidence and mortality in humans, according to studies by the NCBI. According to the WHO, 36.7% of all males and 7.8% of all women consumed tobacco worldwide in 2020, making up 22.3% of the global population. In the UK, there were 6.9 million adult smokers in 2021 equating to 13.3% of adults (aged 18+) according to Cancer Research UK. This huge population engaged in smoking and tobacco indicates higher cases of colorectal cancer cases shortly thus widening the colorectal cancer screening market.

Rising Older Population and Chronic Inflammatory Diseases

The majority of instances affect persons over 50 years of age. The Mayo Clinic reports that colon cancer rates among persons under 50 have been rising. According to the American Cancer Society, 80,010 out of a total of 147,950 colorectal cancer cases were reported in individuals aged 65 years or above i.e., around 50% of total cases. The rising older population is therefore contemplated to bolster the colorectal cancer screening market. For instance, people aged 60 years or above are projected to reach 1.4 billion by 2030 from 1 billion in 2020 according to the WHO estimates.

Increased Awareness about Colorectal Cancer

Multiple campaigns to increase awareness among people coupled with technological innovation are positively driving the colorectal cancer screening market. For instance, US people aged 45 years or older are educated about the value of routine colorectal cancer screenings as part of the CDC's Screen for Life: National Colorectal Cancer Action Campaign. Moreover, in April 2023, the International Agency for Cancer Research published an inaugural report under its Can5 initiative on cancer screening in five continents.

North America is Expected to Grow Significantly

The North American region is expected to hold a significant share of the colorectal cancer screening market during the forecast period. Various factors attributed to such a share are an educated population, government programs, and a higher prevalence of colorectal-causing factors such as smoking and a sedentary lifestyle. For instance, Around 1,600 American teenagers under the age of 18 light up their first cigarette every day, and 16 million additional people suffer from a serious ailment brought on by smoking as per the CDC data. Moreover, the presence of major market leaders such as Exact Science Corporation, and Polymedco Inc. are further expected to aid the colorectal cancer screening market.

Major Market Players

Exact Science Corporation is a US-based molecular diagnostics company that specializes in detection of early-stage cancers. Cologuard is a stool DNA-bases colorectal cancer screening test offered by the company and it is also developing a blood-based screening method for colorectal cancer.
Eiken Chemical Co. Ltd. is one of the leading clinical testing companies. The company launched a fully automated fecal immunochemical test OC-SENSOR Ceres™ in November 2022.

Key Market Developments

In March 2023, in association with CPCRN and NACCD, the CDC introduced a tool for improving the quality of cancer screening for breast, cervical, and colorectal cancers. This package intends to assist community initiatives to boost cancer screening rates and enhance the number of lives saved.
In February 2023, Sanora Quest Labs introduced InSure ONE, its first colorectal cancer home screening kit. In fecal samples, it looks for human hemoglobin to check for lower gastrointestinal bleeding, which could be a symptom of colon cancer.
In May 2022, with just a quick blood draw, Guardant Health introduced the Shield test for colorectal cancer. It doesn't require any more time, anesthesia, specific preparation, or dietary adjustments. It recognizes early indications of CRC signals in the blood.

Segmentation:

By Screening Test

Flexible Sigmoidoscopy
Stool-based Tests
CT Colonography
Colonoscopy
Others

By End-User

Independent Diagnostic Labs
Hospitals
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. COLORECTAL CANCER SCREENING MARKET, BY SCREENING TEST

5.1. Introduction
5.2. Flexible Sigmoidoscopy
5.3. Stool-based Tests
5.4. CT Colonography
5.5. Colonoscopy
5.6. Others

6. COLORECTAL CANCER SCREENING MARKET, BY END USERS

6.1. Introduction
6.2. Independent Diagnostic Labs
6.3. Hospitals
6.4. Others

7. COLORECTAL CANCER SCREENING MARKET, BY GEOGRAPHY

7.1. Introduction
7.2. North America
- 7.2.1. United States
- 7.2.2. Canada
- 7.2.3. Mexico
7.3. South America
- 7.3.1. Brazil
- 7.3.2. Argentina
- 7.3.3. Others
7.4. Europe
- 7.4.1. United Kingdom
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Others
7.5. The Middle East and Africa
- 7.5.1. Saudi Arabia
- 7.5.2. UAE
- 7.5.3. Israel
- 7.5.4. Others
7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.2. China
- 7.6.3. India
- 7.6.4. South Korea
- 7.6.5. Indonesia
- 7.6.6. Thailand
- 7.6.7. Others